AUA 2026: PSA and PFS in Metastatic Prostate Cancer
Medscape,
Hannah D. McManus, MD, reflects on data presented at AUA 2026 in metastatic hormone-sensitive prostate cancer (mHSPC), which…
DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC – US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM
Overview of attention for article published in The Journal of Urology, May 2026
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (90th percentile)
-
Good Attention Score compared to outputs of the same age and source (77th percentile)
Readers on
- mendeley
- 1 Mendeley